NASHVILLE, TENNESSEE – M-LIFE™ has predicted the toxicity profiles across multiple organ systems for a variety of prospective re-purposed COVID-19 drugs. The objective for identifying prospective repurposed drugs is to find on-market therapeutics having the potential to decrease the severity and duration of COVID-19 illness. However, when repurposing existing drugs for a new use, there is the possibility of adverse effects (e.g. toxicity).
M-Life™ President and CEO Ted Moskal said, “When a patient has a raging COVID-19 infection, it’s essentially a war between the virus and the clinicians fighting to save the patient’s life. The battlefield landscape merits discussion when reviewing therapeutic options. About 14 percent of COVID-19 cases require hospitalization, and once hospitalized, 39 percent succumb to the infection (Reference 1, CDC Data). The point here is that COVID-19 is a powerful and aggressive enemy once it takes hold. Aside from vaccines and cytokine storm targeting therapeutics (e.g. defensive weapons), clinicians could really use a good offensive weapon. A good ‘offensive’ therapeutic option must match the COVID-19 assault by being fast acting, and lethal to the virus. Unfortunately, aggressive therapeutics tend to have undesirable toxicities and side effects. Our toxicity algorithms identified a variety of concerns that can be weighed against therapeutic efficacy to avail the best clinical choices.”